Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's UDI Marching Orders: Don't Wait For The Regulation

This article was originally published in The Gray Sheet

Executive Summary

The hoped-for regulation on FDA's unique device identification framework will not come out until the first part of 2011, but companies should start taking steps to implement UDI now, an agency official says.

You may also be interested in...



FDA’s UDI Draft Rule Details Device Marking, Database Submission Mandates

The long-anticipated proposal maps out a unique device identifier system that FDA says will be crucial to the future of post-market safety surveillance, recall management and safety alerts. The effort also will help reduce medical errors and bring an array of other benefits, stakeholders say.

Midwest Hospitals Prepare For Stent Unique-Device-Identifier Demo

The FDA-funded effort out of the Mercy health care system, consisting of 31 hospitals and 200 outpatient facilities in Missouri, Arkansas, Oklahoma and Kansas*, is intended as a demonstration project to help troubleshoot UDIs before a mandatory nationwide system is launched. It is one of two UDI demos in the works in advance of FDA regulations.

Challenges Remain In Linking Unique Device Identifiers To Electronic Health Records

Manufacturers and hospitals have high hopes for the benefits of linking unique device identifiers, still about two years from prime time, to patient electronic health records and registries.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT029652

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel